Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mika Laitinen

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Ultrasonics Sonochemistry|October 12, 2004
Model-based optimization of ultrasonic transducersErkki Heikkola, Mika Laitinen
Biomolecules|May 6, 2020
Differentiation of Murine C2C12 Myoblasts Strongly Reduces the Effects of Myostatin on Intracellular SignalingJuulia H Lautaoja, Satu Pekkala, Arja Pasternack, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 20, 2020
Systemic blockade of ACVR2B ligands attenuates muscle wasting in ischemic heart failure without compromising cardiac functionZoltán Szabó, Laura Vainio, Ruizhu Lin, et al.
Endocrinology|February 2, 2012
A covalently dimerized recombinant human bone morphogenetic protein-15 variant identifies bone morphogenetic protein receptor type 1B as a key cell surface receptor on ovarian granulosa cellsMinna M Pulkki, David G Mottershead, Arja H Pasternack, et al.
Molecular and Cellular Endocrinology|December 29, 2007
Characterization of recombinant human growth differentiation factor-9 signaling in ovarian granulosa cellsDavid G Mottershead, Minna M Pulkki, Pranuthi Muggalla, et al.
Molecular and Cellular Endocrinology|October 13, 2010
The bioactivity of human bone morphogenetic protein-15 is sensitive to C-terminal modification: characterization of the purified untagged processed mature regionMinna M Pulkki, Samu Myllymaa, Arja Pasternack, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 16, 2019
Systemic Blockade of ACVR2B Ligands Protects Myocardium from Acute Ischemia-Reperfusion InjuryJohanna Magga, Laura Vainio, Teemu Kilpiö, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Ultrasonics Sonochemistry|October 12, 2004
Model-based optimization of ultrasonic transducersErkki Heikkola, Mika Laitinen
Biomolecules|May 6, 2020
Differentiation of Murine C2C12 Myoblasts Strongly Reduces the Effects of Myostatin on Intracellular SignalingJuulia H Lautaoja, Satu Pekkala, Arja Pasternack, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 20, 2020
Systemic blockade of ACVR2B ligands attenuates muscle wasting in ischemic heart failure without compromising cardiac functionZoltán Szabó, Laura Vainio, Ruizhu Lin, et al.
Endocrinology|February 2, 2012
A covalently dimerized recombinant human bone morphogenetic protein-15 variant identifies bone morphogenetic protein receptor type 1B as a key cell surface receptor on ovarian granulosa cellsMinna M Pulkki, David G Mottershead, Arja H Pasternack, et al.
Molecular and Cellular Endocrinology|December 29, 2007
Characterization of recombinant human growth differentiation factor-9 signaling in ovarian granulosa cellsDavid G Mottershead, Minna M Pulkki, Pranuthi Muggalla, et al.
Molecular and Cellular Endocrinology|October 13, 2010
The bioactivity of human bone morphogenetic protein-15 is sensitive to C-terminal modification: characterization of the purified untagged processed mature regionMinna M Pulkki, Samu Myllymaa, Arja Pasternack, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 16, 2019
Systemic Blockade of ACVR2B Ligands Protects Myocardium from Acute Ischemia-Reperfusion InjuryJohanna Magga, Laura Vainio, Teemu Kilpiö, et al.
Pageof 1